GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Nanomix Corp (OTCPK:NNMX) » Definitions » Forward Dividend Yield %

Nanomix (Nanomix) Forward Dividend Yield % : 0.00% (As of May. 23, 2024)


View and export this data going back to 2021. Start your Free Trial

What is Nanomix Forward Dividend Yield %?

As of today (2024-05-23), the Forward Annual Dividend Yield of Nanomix is 0.00%.

As of today (2024-05-23), the Trailing Annual Dividend Yield of Nanomix is 0.00%.

NNMX's Forward Dividend Yield % is not ranked *
in the Medical Devices & Instruments industry.
Industry Median: 1.97
* Ranked among companies with meaningful Forward Dividend Yield % only.

Nanomix's Dividends per Share for the three months ended in Dec. 2022 was $0.00.

The growth rate is calculated with least square regression.

For more information regarding to dividend, please check our Dividend Page.


Competitive Comparison of Nanomix's Forward Dividend Yield %

For the Medical Devices subindustry, Nanomix's Forward Dividend Yield %, along with its competitors' market caps and Forward Dividend Yield % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Nanomix's Forward Dividend Yield % Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Nanomix's Forward Dividend Yield % distribution charts can be found below:

* The bar in red indicates where Nanomix's Forward Dividend Yield % falls into.



Nanomix Forward Dividend Yield % Calculation

Dividend Yield measures how much a company pays out in dividends each year relative to its share price.


Nanomix  (OTCPK:NNMX) Forward Dividend Yield % Explanation

Over the long term, the return from dividends has been a significant contributor to the total returns produced by equity securities. Studies by Elroy Dimson, Paul Marsh, and Mike Staunton of Princeton University (2002) found that a market-oriented portfolio, which included reinvested dividends, would have generated nearly 85 times the wealth generated by the same portfolio relying solely on capital gains.

Dividends may also qualify a lower tax rate for investors.

In dividends investing, Payout Ratio and Dividend Growth Rate are the two most important variables for consideration. A lower payout ratio may indicate that the company has more room to increase its dividends.

You can find the stocks that owned most by Gurus here. Or you can check out Warren Buffett's highest dividend stocks here.


Nanomix Forward Dividend Yield % Related Terms

Thank you for viewing the detailed overview of Nanomix's Forward Dividend Yield % provided by GuruFocus.com. Please click on the following links to see related term pages.


Nanomix (Nanomix) Business Description

Traded in Other Exchanges
N/A
Address
2121 Williams Street, San Leandro, CA, USA, 94577
Nanomix Corp develops, manufactures, and commercializes point-of-care diagnostic tests that are used to detect or monitor diseases. Its products include The Nanomix eLab System, COVID-19 Rapid Antigen Panel, and Critical Infection and Host Response. The company's products improve healthcare delivery by bringing the diagnostic information to the point of initial patient interaction, whether in the hospital or settings such as nursing facilities, elderly homes, urgent care centers, airports, schools, and more.
Executives
Chris Hetterly officer: Chief Financial Officer C/O NANOMIX CORPORATION, 2121 WILLIAMS STREET, SAN LEANDRO CA 94577
Garrett Gruener director, 10 percent owner ONE EMBARCADERO CENTER, SUITE 3700, SAN FRANCISCO CA 94111
Thomas Schlumpberger director, officer: CEO C/O NANOMIX CORPORATION, 2121 WILLIAMS STREET, SAN LEANDRO CA 94577
Vidur Sahney officer: Chief Operating Officer C/O NANOMIX CORPORATION, 2121 WILLIAMS STREET, SAN LEANDRO CA 94577
John Hardesky officer: Chief Commercial Officer C/O NANOMIX CORPORATION, 2121 WILLIAMS STREET, SAN LEANDRO CA 94577
David Ludvigson director, officer: CEO and President BLACK PEARL INC, 400 SECOND ST STE 450, SAN FRANCISCO CA 94107
Gregory T Schiffman director 1030 NW JOHNSON ST, UNIT 608, PORTLAND OR 97209
Loraine Upham officer: Chief Operating Officer C/O BOSTON THERAPEUTUCS INC., 354 MERRIMACK ST, #4, LAWRENCE MA 01843
Carl W Rausch director, officer: CEO
Alan M Hoberman director 6134 MECHANICSVILLE ROAD, PO BOX 56, MECHANICSVILLE PA 18934
Cheng Conroy Chi-heng director ADVANCE PHARMACEUTICAL CO LTD, 3/F, GMP CENTRE, 12 DAI FU STREET, TAI PO K3 280
Anthony Don Squeglia officer: Chief Financial Officer PRO-PHARMACEUTICALS, INC., 7 WELLS AVENUE, SUITE 34, NEWTON MA 02459
Neill Sydney Colin director C/O AXONYX INC, 500 SEVENTH AVE 1OTH FLOOR, NEW YORK NY 10018
Jonathan B Rome officer: Chief Operating Officer (3) 178 WEST SADDLE RIVER ROAD, SADDLE RIVER NJ 07458
Rom E Eliaz director 33 KACHAL STREET, LEHAVIM L3 85338

Nanomix (Nanomix) Headlines

From GuruFocus

Nanomix Granted CE Mark for eLab S1 Assay Panel for Whole Blood Samples

By GuruFocusNews GuruFocusNews 06-25-2022

Nanomix Announces Upgrade to OTCQB� Venture Market

By GuruFocusNews GuruFocusNews 06-22-2022

Nanomix Granted CE Mark for eLab S1 Assay Panel for Whole Blood Samples

By GuruFocusNews GuruFocusNews 06-15-2022

Nanomix Granted CE Mark for eLab S1 Assay Panel for Whole Blood Samples

By GuruFocusNews GuruFocusNews 05-26-2022

Nanomix Granted CE Mark for eLab S1 Assay Panel for Whole Blood Samples

By GuruFocusNews GuruFocusNews 06-05-2022

Nanomix Receives IVDR Certification for the eLab Analyzer

By GuruFocusNews GuruFocusNews 06-24-2022

Nanomix Initiates New Clinical Study for the eLab S1 Panel

By GuruFocusNews GuruFocusNews 07-02-2022